IgG Fc engineering to modulate antibody effector functions

Effector-attenuating Substitutions That Maintain Antibody Stability and Reduce Toxicity in Mice

(2017) Megan Lo et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Current progress in innovative engineered antibodies

(2017) William R. Strohl   Protein & Cell

Association of Polymorphisms in FCGR2A and FCGR3A With Degree of Trastuzumab Benefit in the Adjuvant Treatment of ERBB2/HER2–Positive Breast Cancer

(2017) Patrick G. Gavin et al.   JAMA Oncology

Evidence of NI-0101 pharmacological activity, an anti-TLR4 antibody, in a randomized phase I dose escalation study in healthy volunteers receiving LPS

(2016) E Monnet et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Immunoglobulin isotype knowledge and application to Fc engineering

(2016) Randall J Brezski et al.   CURRENT OPINION IN IMMUNOLOGY

Antibodies to watch in 2017

(2016) Janice M. Reichert   mAbs

Structure of FcγRI in complex with Fc reveals the importance of glycan recognition for high-affinity IgG binding

(2015) Jinghua Lu et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Structural basis for binding of human IgG1 to its high-affinity human receptor FcγRI

(2015) Masato Kiyoshi et al.   Nature Communications

Structural insights into the interaction of human IgG1 with FcγRI: no direct role of glycans in binding

(2015) Vaheh Oganesyan et al.   ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY

Potential Mechanisms for Thrombocytopenia Development with Trastuzumab Emtansine (T-DM1)

(2014) H. Uppal et al.   CLINICAL CANCER RESEARCH

Selective Antibody Intervention of Toll-like Receptor 4 Activation through Fc γ Receptor Tethering

(2014) Limin Shang et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Structural Insights into Neonatal Fc Receptor-based Recycling Mechanisms

(2014) Vaheh Oganesyan et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Maximizing the potency of an anti-TLR4 monoclonal antibody by exploiting proximity to Fcγ receptors

(2014) Jérémy Loyau et al.   mAbs

A monoclonal antibody against hinge-cleaved IgG restores effector function to proteolytically-inactivated IgGs in vitro and in vivo

(2014) Randall J Brezski et al.   mAbs

Suppression of innate and adaptive B cell activation pathways by antibody coengagement of FcγRIIb and CD19

(2014) Dániel Szili et al.   mAbs

Regulation of complement and modulation of its activity in monoclonal antibody therapy of cancer

(2014) Saskia Meyer et al.   mAbs

The therapeutic monoclonal antibody market

(2014) Dawn M Ecker et al.   mAbs

Complement Is Activated by IgG Hexamers Assembled at the Cell Surface

(2014) C. A. Diebolder et al.   SCIENCE

A Novel Investigational Fc-Modified Humanized Monoclonal Antibody, Motavizumab-YTE, Has an Extended Half-Life in Healthy Adults

(2013) Gabriel J. Robbie et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Effects of altered FcγR binding on antibody pharmacokinetics in cynomolgus monkeys

(2013) Maya K Leabman et al.   mAbs

Novel asymmetrically engineered antibody Fc variant with superior FcγR binding affinity and specificity compared with afucosylated Fc variant

(2013) Futa Mimoto et al.   mAbs

An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations

(2013) Omid Vafa et al.   METHODS

Engineered antibody Fc variant with selectively enhanced Fc RIIb binding over both Fc RIIaR131 and Fc RIIaH131

(2013) F. Mimoto et al.   PROTEIN ENGINEERING DESIGN & SELECTION

The Immunologic Functions of the Neonatal Fc Receptor for IgG

(2012) Timo Rath et al.   JOURNAL OF CLINICAL IMMUNOLOGY

Avidity confers FcγR binding and immune effector function to aglycosylated immunoglobulin G1

(2012) Thomas C. Nesspor et al.   JOURNAL OF MOLECULAR RECOGNITION

Marketing approval of mogamulizumab

(2012) Alain Beck et al.   mAbs

Disulfide bond structures of IgG molecules

(2012) Hongcheng Liu et al.   mAbs

Structural Basis for Fc RIIa Recognition of Human IgG and Formation of Inflammatory Signaling Complexes

(2011) P. A. Ramsland et al.   JOURNAL OF IMMUNOLOGY

Unique carbohydrate-carbohydrate interactions are required for high affinity binding between Fc RIII and antibodies lacking core fucose

(2011) C. Ferrara et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

IgG2m4, an engineered antibody isotype with reduced Fc function

(2010) Zhiqiang An et al.   mAbs

Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector functions

(2010) Gregory L. Moore et al.   mAbs

Enhanced antibody half-life improves in vivo activity

(2010) Jonathan Zalevsky et al.   NATURE BIOTECHNOLOGY

Inhibitory ITAMs as novel regulators of immunity

(2009) Ulrich Blank et al.   IMMUNOLOGICAL REVIEWS

Impact of FcγRIIa-FcγRIIIa Polymorphisms and KRAS Mutations on the Clinical Outcome of Patients With Metastatic Colorectal Cancer Treated With Cetuximab Plus Irinotecan

(2009) Frédéric Bibeau et al.   JOURNAL OF CLINICAL ONCOLOGY

Engineered Antibodies of IgG1/IgG3 Mixed Isotype with Enhanced Cytotoxic Activities

(2008) A. Natsume et al.   CANCER RESEARCH

Molecular engineering and design of therapeutic antibodies

(2008) Leonard G Presta   CURRENT OPINION IN IMMUNOLOGY

Optimization of antibody binding to Fc RIIa enhances macrophage phagocytosis of tumor cells

(2008) J. O. Richards et al.   MOLECULAR CANCER THERAPEUTICS

Inhibition of B cell receptor-mediated activation of primary human B cells by coengagement of CD19 and FcγRIIb with Fc-engineered antibodies

(2008) Seung Y. Chu et al.   MOLECULAR IMMUNOLOGY

Structural characterization of a mutated, ADCC-enhanced human Fc fragment

(2008) Vaheh Oganesyan et al.   MOLECULAR IMMUNOLOGY